Evaluating Parp1 domains as gossypol targets
- 作者: Gross S.1, Kotova E.Y.1, Maluchenko N.V.2, Pascal J.M.3, Studitsky V.M.1,2
-
隶属关系:
- Cancer Epigenetics Team
- Department of Biology
- Department of Biochemistry and Molecular Medicine
- 期: 卷 71, 编号 4 (2016)
- 页面: 235-239
- 栏目: Molecular Biology
- URL: https://journals.rcsi.science/0096-3925/article/view/173569
- DOI: https://doi.org/10.3103/S0096392516040106
- ID: 173569
如何引用文章
详细
Poly ADP-ribose Polymerase 1 (PARP1) is an important enzyme that is involved in DNA repair, replication, and transcription. Prospective anticancer drug gossypol inhibits human PARP1, but the mechanism of inhibition remains unknown. It has been shown previously that gossypol interacts with purified BRCA1 C-terminus (BRCT) domain in vitro. However, it remained unclear whether gossypol inhibits PARP1 through the BRCT domain in the context of full-length protein. Here, we report that the BRCT domain within the full-length PARP1 protein is not required for the inhibition of catalytic activity of PARP1 by gossypol. Our results, obtained using a series of PARP1 mutations and H4-dependent pathway of PARP1 activation, also show that none of the zinc fingers or other DNA binding domains of PARP1 are involved in the inhibition of the PARP1 catalytic activity by gossypol. Thus, the likely candidate target(s) for gossypol action are the other domains of PARP1, or the interdomain linkers.
作者简介
S. Gross
Cancer Epigenetics Team
Email: mal_nat@mail.ru
美国, Philadelphia, PA, 19111
E. Kotova
Cancer Epigenetics Team
Email: mal_nat@mail.ru
美国, Philadelphia, PA, 19111
N. Maluchenko
Department of Biology
编辑信件的主要联系方式.
Email: mal_nat@mail.ru
俄罗斯联邦, Moscow, 119234
J. Pascal
Department of Biochemistry and Molecular Medicine
Email: mal_nat@mail.ru
加拿大, Montréal, QC, H3C 3J7
V. Studitsky
Cancer Epigenetics Team; Department of Biology
Email: mal_nat@mail.ru
美国, Philadelphia, PA, 19111; Moscow, 119234
补充文件
